Lino-M XR Tablet 5 mg+1000 mg is an extended-release fixed-dose combination of Linagliptin (5 mg), a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, and Metformin Hydrochloride (1000 mg), a biguanide. This formulation is intended for adults with type 2 diabetes mellitus who require enhanced glycemic control through dual therapy. The extended-release (XR) formulation allows for once-daily dosing, improving convenience and adherence while minimizing gastrointestinal side effects commonly associated with immediate-release metformin.

Linagliptin inhibits the DPP-4 enzyme, increasing levels of active incretin hormones such as GLP-1 and GIP. This enhances glucose-dependent insulin secretion from pancreatic beta cells and reduces glucagon release from alpha cells, which helps regulate both fasting and postprandial glucose levels.

Metformin Hydrochloride works synergistically by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving peripheral insulin sensitivity. Together, Linagliptin and Metformin target multiple mechanisms of hyperglycemia, providing comprehensive control over blood glucose.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Lino-M XR Tablet 5 mg+1000 mg is indicated for:

• Adults with type 2 diabetes mellitus inadequately controlled by diet, exercise, or monotherapy

• Patients requiring combination therapy to achieve optimal glycemic control

• Situations where once-daily dosing is preferred for better patient adherence

It is not suitable for type 1 diabetes mellitus or diabetic ketoacidosis.

Therapeutic Class

• Dipeptidyl Peptidase-4 (DPP-4) inhibitor

• Biguanide (Metformin)

Pharmacology

Linagliptin:

• Inhibits DPP-4 enzyme, preventing breakdown of incretin hormones

• Enhances glucose-dependent insulin secretion

• Suppresses inappropriate glucagon release, reducing hepatic glucose output

Metformin Hydrochloride:

• Decreases hepatic gluconeogenesis

• Increases glucose uptake in peripheral tissues

• Reduces intestinal glucose absorption

The combination of Linagliptin and Metformin XR provides dual action against both insulin deficiency and insulin resistance, improving long-term glycemic control with a reduced risk of hypoglycemia.

Dosage & Administration

• Adults: Take one tablet once daily with meals to reduce gastrointestinal discomfort

• Do not crush or chew the XR tablet; swallow whole

• Can be used alongside other antidiabetic medications as prescribed

• No dose adjustment is typically required for mild renal impairment; caution is needed in moderate or severe cases

Contraindications

• Hypersensitivity to Linagliptin, Metformin, or any component of the tablet

• Severe renal impairment, acute or chronic metabolic acidosis, or diabetic ketoacidosis

• Conditions increasing the risk of lactic acidosis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Potential side effects include:

• Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain

• Hypoglycemia, particularly when combined with sulfonylureas or insulin

• Rare: pancreatitis, lactic acidosis, allergic reactions, rash

Precautions & Warnings

• Monitor renal function regularly

• Use caution in patients with liver disease, heart failure, or alcohol use

• Temporarily discontinue metformin during radiologic studies using iodinated contrast

• Educate patients about lactic acidosis signs (fatigue, muscle pain, rapid breathing)

Pregnancy & Lactation

• Pregnancy Category B: Use only if clearly necessary

• Unknown whether the medication passes into breast milk; use under medical supervision

Storage

Store in a cool, dry place below 30°C, away from light and moisture. Keep out of reach of children.

Lino-M XR Tablet 5 mg+1000 mg provides a convenient once-daily dual therapy for adults with type 2 diabetes, combining the complementary mechanisms of Linagliptin and Metformin XR to improve glycemic control safely and effectively.